Tice RR, Bassan A, Amberg A, Anger LT, Beal MA, Bellion P, Benigni R, Birmingham J, Brigo A, Bringezu F, Ceriani L, Crooks I, Cross K, Elespuru R, Faulkner DM, Fortin MC, Fowler P, Frericks M, Greets HHJ, Jahnke GD, Jones DR, Krulak NL, Piparo EL, Lopez-Belmonte J, Luniwal A, Luu A, Madia F, Manganelli S, Manickam B, Mestres J, Mihalchik-Burhans AL , Neilson L, Pandiri A, Pavan M, Rider CV, Rooney JP, Trejo-Martin A, Wantanabe-Sailor KH, White AT, Wooley D, Myatt GJ. 2021. In silico approaches in carcinogenicity hazard assessment: Current status and future needs. Comp Toxicol 20:100191 (Special issue: The in silico toxicology protocols initiative).
View Abstract
Publication: Manuscripts
2021 (1 POST)
Hackshaw A, Cohen SS, Reichert H , Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer, open access .
View Abstract
Publication: Manuscripts
2020 (7 POSTS)
Bylsma LC , Gillezeau C, Garawin TA, Kelsh MA , Fryzek JP , Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.
View Abstract
Publication: Manuscripts
Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA , et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.
View Abstract
Publication: Manuscripts
Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA , et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.
View Abstract
Publication: Manuscripts
Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA , et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.
View Abstract
Publication: Manuscripts
Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA . 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.
View Abstract
Publication: Manuscripts
Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA , et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.
View Abstract
Publication: Manuscripts
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M , et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.
View Abstract
Publication: Manuscripts
2019 (1 POST)
Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M , et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.
View Abstract
Publication: Manuscripts
2016 (6 POSTS)
Garabrant DH, Alexander DD, Miller PE, Fryzek JP , Boffetta P, Teta MJ, … Kelsh MA , et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.
View Abstract